Rationale and Design of the ICON-RELOADED Study: International Collaborative of Nterminal pro-B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency Department by Gaggin, Hanna Kim et al.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Trial Design 
Rationale and Design of the ICON-RELOADED Study: International Collaborative of N-
terminal pro-B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the 
Emergency Department 
Brief Title (45 characters): ICON-RELOADED Study Design and Rationale 
Gaggin HK, MD, MPH*
†‡
; Chen-Tournoux AA, MD
§
; Christenson RH, PhD
‖
; Doros G, PhD
‡¥
;
Hollander JE, MD
¶
; Levy PD, MD
#
; Nagurney JT, MD*
†
; Nowak RM, MD**; Pang PS, MD,
MS
††
; Patel D, MS
‡‡
; Peacock WF, MD
§§
; Walters EL, MD
‖‖
; and Januzzi JL, MD*
†‡ 
on behalf of
the ICON-RELOADED Investigators.
* Massachusetts General Hospital, Boston, MA, USA
†
Harvard Medical School, Boston, MA, USA 
‡
Baim Institute for Clinical Research, Boston, MA, USA 
§
Jewish General Hospital, Montreal, PQ, Canada 
‖
University of Maryland School of Medicine, Baltimore, MD, USA 
¥
Department of Biostatistics, Boston University, MA, USA
¶
Jefferson University, Philadelphia, PA, USA 
#
Wayne State University, Detroit, MI, USA 
**
Henry Ford Health System, Detroit, MI, USA 
††
Indiana University School of Medicine & Indianapolis EMS, Indianapolis, IN, USA 
‡‡
Roche Diagnostics, Indianapolis, IN, USA 
§§
 Baylor College of Medicine, Houston, TX, USA 
‖‖
 Loma Linda University Medical Center, Loma Linda, CA, USA
Address for Correspondence: 
James L. Januzzi, Jr, MD, FACC, FESC 
Massachusetts General Hospital 
Yawkey 5B, Boston, MA, 02114 
P: 617-726-3443, F: 617-643-1620 
JJanuzzi@mgh.harvard.edu 
Funded by Roche Diagnostics, Inc. 
Word Count: 4124 words. 
Conflicts of Interest 
Dr. Gaggin has received grant support from Roche Diagnostics and Portola; consulting income 
from Roche Diagnostics, Amgen, Boston Heart Diagnostics and Ortho Clinical; research 
payments for clinical endpoint committees for EchoSense and Radiometer. Dr. Chen-Tournoux 
has received consulting income from Roche Diagnostics. Dr. Christenson has received support 
from Roche Diagnostics, Siemens Healthcare Diagnostics, Beckman Coulter, Spingotech, Ortho 
_________________________________________________________________________________
 
This is the author's manuscript of the article published in final edited form as: 
Gaggin, H., Chen-Tournoux, A., Christenson, R., Doros, G., Hollander, J., Levy, P., … Januzzi, J. (2017). Rationale and Design of the 
ICON-RELOADED Study: International Collaborative of N-terminal pro-B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic 
Cut-Offs in the Emergency Department. American Heart Journal. https://doi.org/10.1016/j.ahj.2017.07.002
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
2 
 
Clinical Diagnostics, and Abbott. Dr. Doros has received consulting income from Pfizer, 
Genzyme, and Sarepta. Dr. Hollander has received support from PCORI, NIH, Alere, Siemens, 
Roche, Portola, and Trinity. Dr. Levy has received support from PCORI, NIH, Siemens, Roche, 
Thermofisher, Amgen, Novartis, Trevena, Cardiorentis, and ZS Pharma. Dr. Nagurney has 
received grant support from Roche Diagnostics, Alere/Biosite, Boehringer Ingelheim, Thermo 
Fisher and Nanosphere. Dr. Nowak receives grant support from Roche Diagnostics, Siemens, 
Abbott, Novartis, and Radiometer, and is a consultant for Roche, Siemens, Abbott, Trinity, and 
Thermofisher.  Dr. Pang is or has been in the past one year a consultant for BMS, Novartis, 
Trevena, scPharmaceuticals, Roche Diagnostics, and Relypsa, and has received research support 
from Roche, Novartis, PCORI, IUSM, Indianapolis EMS. Ms. Patel was an employee of Roche 
Diagnostics. Dr. Peacock has received grants support from Abbott, Alere, Banyan, Cardiorentis, 
Janssen, Pfizer, Roche, The Medicine’s Company, ZS Pharma; has served as a consultant for 
Alere, Cardiorentis, Ischemia Care, Janssen, Phillips, Prevencio, The Medicine's Company, ZS 
Pharma; and has ownership interests in Comprehensive Research Associates LLC, and 
Emergencies in Medicine LLC. Dr. Walters received investigator funding for this study from 
Roche Diagnostics. Dr. Januzzi has received grant support from Siemens, Singulex and 
Prevencio; consulting income from Roche Diagnostics, Critical Diagnostics, Sphingotec, 
Phillips, and Novartis; and participates in clinical endpoint committees/data safety monitoring 
boards for Novartis, Amgen, Janssen, and Boehringer Ingelheim. 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
3 
 
ABSTRACT:  
Objectives: To re-assess use of amino-terminal pro B-type natriuretic peptide (NT-proBNP) 
concentrations for diagnosis and prognosis of acute heart failure (HF) in patients with acute 
dyspnea. 
Background: NT-proBNP facilitates diagnosis, prognosis, and treatment in patients with 
suspected or proven acute HF. As demographics of such patients are changing, previous 
diagnostic NT-proBNP thresholds may need updating. Additionally, value of in-hospital NT-
proBNP prognostic monitoring for HF is less understood.   
Methods: In a prospective, multicenter study in the United States and Canada, patients 
presenting to emergency departments with acute dyspnea were enrolled, with demographic, 
medication, imaging and clinical course information collected. NT-proBNP analysis will be 
performed using the Roche Diagnostics Elecsys
®
 proBNPII immunoassay in blood samples 
obtained at baseline and at discharge (if hospitalized). Primary endpoints include positive 
predictive value (PPV) of previously established age-stratified NT-proBNP thresholds for the 
adjudicated diagnosis of acute HF, and its negative predictive value (NPV) to exclude acute HF. 
Secondary endpoints include sensitivity, specificity, and positive and negative likelihood ratios 
for acute HF and among those with HF the prognostic value of baseline and pre-discharge NT-
proBNP for adjudicated clinical endpoints (including all-cause death and hospitalization) at 30 
and 180 days.  
Results: 1461 dyspneic subjects have been enrolled and are eligible for analysis.  Follow-up for 
clinical outcome is ongoing. 
Conclusions: The International Collaborative of N-terminal pro-B-type Natriuretic Peptide Re-
evaluation of Acute Diagnostic Cut-Offs in the Emergency Department study offers a 
contemporary opportunity to understand best diagnostic cutoff points for NT-proBNP in acute 
HF, and validate in-hospital monitoring of HF using NT-proBNP. 
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ABBREVIATIONS: 
CI: confidence interval 
ED: emergency department 
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HFpEF: heart failure with preserved ejection fraction 
HFrEF: heart failure with reduced ejection fraction 
ICON: International Collaborative of NT pro-BNP 
LR-: negative likelihood ratio 
LR+: positive likelihood ratio 
NT-proBNP: N-terminal pro B-type natriuretic peptide 
NPV: negative predictive value 
PPV: positive predictive value 
PRIDE: N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
5 
 
Acute heart failure (HF) can be challenging to diagnose, as symptoms and signs often overlap 
with other conditions, leading to both under and over recognition, and incorrect treatment. 
Testing of blood for the presence of natriuretic peptides facilitates the diagnosis, as well as 
provides an objective indication of the severity and prognosis, of HF.  B-type natriuretic peptide 
(BNP), and its amino-terminal pro-peptide cleavage equivalent, NT-proBNP, are both sensitive 
and specific biomarkers for the diagnosis of acute HF (1-4).
 
In prospective, randomized clinical 
trials of patients presenting with symptoms of acute dyspnea, natriuretic peptides improved 
clinician diagnostic accuracy for acute HF,(5) reduced health care expenditures, and improved 
outcomes compared with clinical judgment alone.(6)  
Though embedded as a Class I Level of Evidence A in clinical practice guidelines for diagnostic 
evaluation of HF (7), questions remain regarding the current use of natriuretic peptides.  In the 
past few decades, considerable changes in HF demographics have occurred. Patients with HF are 
generally older, with more co-morbidities such as atrial fibrillation, anemia, and chronic kidney 
disease;(8) all of these differences may cause higher than expected natriuretic peptide 
concentrations.(9)  Drugs for HF (i.e., sacubitril/valsartan), which directly raise BNP 
concentrations and simultaneously lower NT-proBNP, are now available. Conversely, compared 
to earlier decades, there is increasing incidence and prevalence of HF with preserved ejection 
fraction (HFpEF) and patients are generally more obese,(10, 11) both of which may cause lower-
than-expected natriuretic peptide concentrations.(12, 13)  Accordingly, presently utilized 
diagnostic thresholds for natriuretic peptides may require a re-assessment.   
For NT-proBNP, historical regulatory-approved thresholds were based on data generated from 
testing in non-acute patients, a population different from typical patients encountered in the 
emergency department (ED); Moreover, these cutoffs were developed for their high negative 
predictive value (NPV), with the intent of excluding HF, rather than for their positive predictive 
value (PPV) in identifying HF. While NPV is of value, identification of PPV-optimized cut-offs 
is important as well.  In this regard, the N-Terminal Pro-BNP Investigation of Dyspnea in the 
Emergency Department (PRIDE) and International Collaborative of NT-proBNP (ICON) studies 
identified PPV-optimized cut-offs for the identification of acute HF.  In these studies, an 
approach of using diagnostic thresholds of 450 pg/mL, 900 pg/mL and 1800 pg/mL for age 
categories of <50, 50–75 and >75 years, respectively, was considerably more accurate, 
improving specificity without sacrificing sensitivity(14). While both the age-stratified NT-
proBNP approach and the NPV-optimized cut off of 300 pg/mL to exclude acute HF has been 
endorsed by clinical practice guidelines (7), consensus statements, (15) and top-tier research 
journal summaries (16), regulatory-approved thresholds for NT-proBNP remain unchanged for 
use in acute dyspnea, leading to considerable confusion. Thus, opportunities exists not only to 
validate age-stratified cut-points for NT-proBNP, but to do so in a more contemporary cohort.   
Beyond diagnosis, NT-proBNP also facilitates assessment of HF severity as well as the 
prediction of prognosis in patients with acute HF(14, 17, 18).  While concentrations of NT-
proBNP at presentation with acute HF are strongly prognostic, post-treatment concentrations are 
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even more powerfully predictive of hospitalization or death; accordingly, recent enthusiasm has 
grown in use of NT-proBNP for prognostic monitoring during hospital treatment for acute HF. 
However, although retrospective data suggest in-hospital change in NT-proBNP may be useful 
for prognosis,(19-23), prospectively collected data are limited.   
Accordingly, the primary aim of this study is to validate the ICON cut-offs in a contemporary 
cohort. Additionally, as a secondary aim, this study will prospectively evaluate the value of in-
hospital NT-proBNP monitoring for prediction of clinical outcomes. The design, population, 
endpoints, and statistical considerations for the International Collaborative of N-terminal pro-B-
type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency 
Department (ICON-RELOADED) Study are described. 
METHODS  
The institutional review board at each participating institution approved the study, and all 
patients provided written informed consent prior to enrollment. Funding was provided by Roche 
Diagnostics. Joanna Suomi, MSc, contributed to the writing and editing of this manuscript as an 
employee of the Baim Institute for Clinical Research. 
Study Design, Setting, and Evaluations 
The ICON-RELOADED Study is a prospective, multicenter clinical trial conducted at 19 sites in 
the United States and Canada (Figure 1).  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
7 
 
Figure 1: Study site distribution. A wide range of sites enrolled 1461 patients and provided a
balanced demographic of patients.
Abbreviations: BIDMC, Beth Israel Deaconess Medical Center; MGH, Massachusetts General Hospital. 
A total of 1461 patients presenting to ED with acute dyspnea were enrolled between October 
2015 and October 2016. As seen in Table 1, blood samples were collected at enrollment and at 
hospital discharge (unless the patient was discharged from the emergency department). Post 
discharge clinical events were obtained at 180 days (±14 days) via phone call with patient or 
primary care physician when needed.  
Table 1. ICON-RELOADED timeline. 
Evaluations at 
Enrollment
Evaluations at 
Discharge
Evaluations at 
180 ±14 Days
Oct 2015 – Oct 2016 Apr 2016 –
Apr 2017
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NT-proBNP and biorepository blood samples X X*  
DNA sample** X   
Clinical course X X X 
Concomitant medications X X X 
Adverse events X X X 
*If patients were discharged from ED directly home, no discharge sample had to be collected. There may have been 
an additional pre-discharge blood draw if the subject remained in hospital for more than 24 hours since the previous 
pre-discharge blood draw.  
**
 
To be drawn from those that consented to this procedure. 
 
Study Objectives 
The primary objective of this study is to externally validate the use of Elecsys® proBNP (Roche 
Diagnostics, Indianapolis, IN, USA) concentrations to aid in the diagnosis of HF in patients 
presenting emergently through use of the ICON cut-point strategy(14). This will identify (“rule 
in”) or exclude (“rule out”) the diagnosis of acute HF (Table 2). 
 
Table 2: Proposed NT-proBNP cut-points for diagnosis or exclusion of acute heart failure.  
Based on earlier studies, these thresholds will be re-evaluated in the ICON-RELOADED Study. 
Threshold for Diagnosis of Acute HF Patient Age Group 
450 pg/mL <50 years 
900 pg/mL 50–75 years 
1800 pg/mL ≥75 years 
Threshold for Exclusion of Acute HF Patient Age Group 
300 pg/mL N/A 
 
As a secondary aim, we will determine the value of in-hospital change of NT-proBNP relative to 
other clinical and biochemical variables predicting post-discharge outcomes. 
Study Population 
Patients presenting to emergency departments with acute dyspnea were enrolled if they met all of 
the inclusion criteria and had no exclusion criteria, as listed in Table 3.  
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Table 3. Patient eligibility criteria.  A patient had to meet all of the listed inclusion criteria to 
participate in the study.  A patient was excluded from participation if s/he met any of the clinical 
exclusion criteria, and a sample was excluded from the study if it met any of the sample 
exclusion criteria. 
Enrollment 
Inclusion 
Criteria 
Age ≥ 22 years 
Admission to the emergency department with acute dyspnea  
Written informed consent 
Clinical 
Exclusion 
Criteria 
Renal insufficiency requiring dialysis or known estimated glomerular filtration rate <15 
mL/min/1.73 m
2 
prior to enrollment 
Dyspnea after chest trauma 
Subject unable to donate up to 50 mL of blood at one time 
Known pregnancy 
Unreliable or non-compliant, including patients with known history of active alcoholism, 
drug abuse, or serious psychiatric disorder that may lead to noncompliance; as well as 
patients unwilling to abide by the requirements of the protocol 
Any known conditions (e.g. psychiatric history, language barrier, absence of legal 
representative, etc.) that would interfere with the patient’s ability to comply with study 
instructions, might confound the interpretation of the study, or put the patient at risk 
Personnel, or any relative of personnel of the Sponsor, the Contract Research Organization, 
or the investigative site(s) 
Sample 
Exclusion 
Criteria 
Visible hemolysis, lipemia or icterus 
Known interferents with NT-proBNP assay such as high dose biotin use. 
Visible particulates 
Insufficient quantity 
Specimens not collected, handled, stored or shipped properly 
 
Biorepository 
Fifty (50) mL of blood was collected from each patient enrolled using serum, Lithium-Heparin 
(Li-Hep) Plasma, and ethylene-diamineteraacetic acid (EDTA) tubes, with DNA extraction 
performed from the EDTA tube. Serum tubes sat at room temperature to allow the clot to form. 
Plasma tubes were immediately stored at 2-8°C prior to centrifugation. A subject that did not 
have at least 8, 0.30 mL aliquots from the Li-Hep Plasma tube was designated as a “dropped” 
subject for enrollment status. If less than 8, 0.30 mL aliquots were obtained from the EDTA 
tubes, the subject was not “dropped” as the primary matrix of interest for regulatory approval 
will be Li-Hep; the EDTA samples will be utilized for creation of a biorepository for assessing 
novel HF markers of interest while cross-validating quality performance NT-proBNP assays in 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
10 
 
different matrices. Samples were stored at -70⁰C or colder, and shipped to the ICON-
RELOADED Biorepository.  
For discharge blood samples, 50 mL of blood was collected, also the same protocol, within 24 
hours of planned discharge.  
Samples will be maintained in the ICON-RELOADED Biorepository until the time of NT-
proBNP testing (<1 year), which will be performed using the commercially available Elecsys 
proBNP II (Roche Diagnostics, Indianapolis, IN) immunoassay, according to established 
methods. 
Study Endpoints 
Primary Efficacy Endpoints 
The primary efficacy endpoints for this study are the positive predictive value (PPV) of age-
specific rule-in thresholds of 450/900/1800 pg/mL for ages <50/50-75/≥75 years for the 
diagnosis of acute HF, and the negative predictive value (NPV) of the rule-out threshold of 300 
pg/mL to exclude the adjudicated diagnosis of acute HF.  
Secondary Efficacy Endpoints.  
Secondary endpoints include the NPV, positive likelihood ratio (LR+), negative likelihood ratio 
(LR–), sensitivity and specificity for the age-specific rule-in thresholds as well as the PPV, LR+, 
LR-, sensitivity and the specificity for the rule-out threshold.  
In addition, all efficacy endpoints will be evaluated by region (United States and Canada) for 
regulatory purposes. 
Secondary Clinical Endpoints  
We will assess the following clinical outcomes at 30- and 180-days post discharge: major 
adverse cardiac events following index presentation or hospitalization (MACE, a composite of 
all-cause death or HF hospitalization), all-cause death, cardiac death, all-cause hospitalization 
and HF hospitalization. Using baseline and discharge characteristics as well as NT-proBNP 
concentrations at baseline and discharge, we will develop a multivariable model for the 
prediction of clinical outcomes.  
Statistical Considerations 
Sample Size Calculation 
The study was designed to include 1765 patients to ensure a sample of at least 1500 analyzable 
patients, accounting for an assumed attrition rate of approximately 15%. A maximum of 15% of 
patients were to be enrolled from sites in Canada, thereby intending 1500 enrolled and 1275 
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analyzable patients from the United States, and 265 enrolled and 225 analyzable patients from 
Canada.  
Statistical Analyses 
Efficacy Endpoints 
Operating characteristics of the proposed age-based thresholds combined (for rule-in) and the 
proposed threshold for rule-out relative to the gold-standard diagnosis will be evaluated, 
including sensitivity, specificity, PPV, NPV, LR+ and LR–. Estimates and CIs for the NPV and 
PPV parameters will be determined.(24) Estimates, CIs and tests for the likelihood ratios 
parameters, LR+ and LR–, will be carried out using a non-linear mixed effects model. Based on 
data generated in the ICON study,(14) overall sensitivity and specificity of the proposed age-
dependent thresholds are expected to be 90.0% and 84.0%, respectively. The expected PPV is 
85.0% and the LR+ is estimated at 5.62.  
With a planned sample size of 1,500 analyzable patients and an assumed prevalence of HF of 
50% in this population,(14) the lower bound of a 95% two-sided CI for the hypothesized PPV is 
82.6% while for lower bound for the hypothesized LR+ is expected to be 4.77, which would 
establish the proposed test as a useful tool to aid diagnosis of acute HF in this population.(25) A 
planned sample of 1,275 analyzable patients from the United States would result in lower bounds 
of a two-sided 95% CI for the PPV of 82.5% and for LR+ of 4.6, therefore providing substantial 
precision. 
With a proposed rule-out threshold of 300 pg/mL, the expected sensitivity and specificity values 
are 99.0% and 60.0%, respectively.(14) Thus, the expected NPV is 98.5% and the LR– is 0.017, 
with a lower bound for a two-sided 95% CI for the NPV of 96.7% and a upper bound for a two-
sided 95% CI of 0.034, thereby establishing the proposed test as a useful tool in the aid of 
excluding acute HF in this population.(25)  
Clinical Endpoints 
Univariable comparison of baseline and discharge characteristics (NT-proBNP concentrations, as 
below) between patients with and without a composite endpoint of all-cause death or repeat HF 
hospitalization will be assessed at 30 and 180 days post discharge using χ2 test for categorical 
variables and Mann-Whitney for continuous variables. Normally distributed variables are 
presented as mean ± standard deviation and non-normally distributed variables are shown as 
median with interquartile range. Age, sex and other variables that are statistically significant will 
be considered as a candidate variable in a multivariable prediction of the time-to composite 
endpoint with a retention value of p>0.1 in a Cox proportional hazard model. Co-linearity will be 
assessed and non-parametric continuous variables will be transformed to fit a normal curve. 
Concentrations of NT-proBNP will be assessed as absolute values at baseline and discharge as 
well as change from baseline to discharge (absolute difference as well as relative percent change 
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from baseline value). A responder will be defined as relative percent difference in NT-proBNP 
from baseline to discharge ≥30% and a non-responder will be defined as NT-proBNP change 
<30%. In addition, multivariable prediction models for re-hospitalization will be performed 
using multivariable logistic regression.  
Diagnostic Subgroups of Interest  
As it is well-known that NT-proBNP may be influenced by certain important medical co-
morbidities, diagnostic subgroups of interest have been pre-specified. These include (1) HF with 
reduced EF (HFrEF) versus HFpEF (defined as left ventricular EF <50% vs. ≥50%); (2) sex; (3) 
race (black vs. non-black); (4) obesity (body mass index <30.0 vs. ≥30.0 kg/m2); (5) with or 
without a history of atrial fibrillation; and (6) with or without renal insufficiency (eGFR ≤60.0 
mL/min/1.73m
2
 vs. eGFR >60.0 mL/min/1.73m2). Because decompensation of chronic HF is a 
very important predictor of the diagnosis of acute HF, we will evaluate discrimination and 
operating characteristics of NT-proBNP in patients with acute on chronic as well as de novo HF. 
Clinical Event Adjudication  
The Clinical Events Committee (CEC) includes a panel of physicians (cardiologists and 
emergency physicians) who are independent from the study. CEC meetings will include a 
minimum of 2 emergency physicians and 1 cardiologist or interventional cardiologist for the 
adjudication of pre-specified clinical endpoints based on charter-based criteria used for the 
categorization of clinical events in the study (see Appendix for definitions).   
Assessment of HF 
For the assessment of HF diagnosis, the members of the CEC will be blinded to local site NT-
proBNP or BNP concentrations during index hospitalization, if performed for standard of care.  
Adjudication will be performed prior to the performance of central laboratory NT-proBNP 
testing for regulatory submission. The CEC will adjudicate the diagnosis for each patient at 
presentation, categorized as acute HF, acute HF and additional active diagnosis (e.g., pulmonary, 
other cardiac, anemia), other diagnosis and no HF (incident or prevalent), or other diagnosis and 
prior background of HF without acute decompensation.  
Endpoint Assessment 
For assessment of clinical events and clinical endpoints, all available information is provided to 
the members of the CEC, excluding the CEC adjudication for index hospitalization acute HF 
diagnosis. The CEC will adjudicate all hospitalizations, deaths, and other clinical events that 
occur throughout the trial (to 180 [+/- 14] days).  
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RESULTS 
Study enrollment ended October 15, 2016, with 1758 patients included (signed the informed 
consent form). Of these, 297 were excluded due to clinical or sample exclusion criteria, leaving 
1461 enrolled, of which 1424 were from the United States and 37 were from Canada (Figure 2).   
 
Figure 2. CONSORT Diagram. Of 1758 patients included (signed the informed consent form), 
297 (17%) were excluded due to subsequent clinical or sample exclusion criteria, leaving 1461 
patients enrolled, with a blood sample available for analysis. 
* Data are presented non-hierarchically; 2 patients also had sample exclusion criteria but are only 
counted in this box.  
† 57 patients included in this box met the clinical criteria but did not have a baseline blood sample. 
As seen in Table 4, patients were a mean of 56.4 ±15.7 years old, 49.1% were female, and 
40.4% were non-white race. Overall, 63.3% of patients had history of hypertension, 24.9% had 
prior HF, and 25.4% had left ventricular ejection fraction <40% at their most recent evaluation 
prior to study enrollment. Asthma was present in 30.1%, chronic obstructive pulmonary disease 
in 27.5%, and a history of lung cancer in 2.8%. A total of 58.5% of patients reported being 
current or former smokers. For the purposes of the prespecified subgroup analyses, it is notable 
that 36.6% of patients were black, 52.5% had BMI ≥ 30, and 24.0% had renal insufficiency (not 
presented). Not all cases of HF had been adjudicated at the time of publication and therefore it is 
not known how many subjects had HFrEF or HFpEF. 
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Table 4: Baseline characteristics of enrolled patients. 
Characteristic 
All Patients 
N=1461 
Demographics  
Age (years) (Mean ± SD (N)) 56.4±15.7 (1461) 
Female Sex 49.1% (718/1461) 
Hispanic or Latino 13.6% (191/1406) 
Non-White Race 40.4% (579/1432) 
Medical History  
Diabetes Mellitus 28.9% (420/1454) 
Hypertension 63.3% (921/1455) 
Heart Failure 24.9% (356/1431) 
Peripheral Arterial Disease 4.3% (61/1434) 
Implantable Cardioverter-Defibrillator 5.9% (86/1452) 
Cardiac Resynchronization Therapy 1.7% (24/1442) 
Coronary Artery Bypass Graft 6.6% (96/1451) 
Prior Coronary Artery Disease 21.2% (307/1445) 
Previous Myocardial Infarction 13.2% (188/1428) 
Previous Percutaneous Coronary Intervention 8.9% (128/1431) 
Renal Insufficiency/Failure 7.8% (114/1455) 
    Dialysis 0.0% (0/114) 
    eGFR <15 mL/min/1.73m
2
 0.0% (0/103) 
LVEF <40% at Most Recent Evaluation Prior to Enrollment 25.4% (103/405) 
Atrial Fibrillation 14.9% (216/1453) 
Significant Mitral Valve Disease 4.2% (57/1372) 
Significant Aortic Valve Disease 2.3% (31/1338) 
Asthma 30.1% (437/1450) 
Chronic Obstructive Pulmonary Disease 27.5% (399/1449) 
History of Lung Cancer 2.8% (40/1454) 
Alcohol History  
    Never 36.6% (514/1404) 
    Former 16.4% (230/1404) 
    Current 47.0% (660/1404) 
Tobacco History  
    Never 41.5% (591/1423) 
    Former 36.7% (522/1423) 
    Current 21.8% (310/1423) 
Cocaine History  
    Never 89.0% (1227/1379) 
    Former 10.4% (144/1379) 
    Current 0.6% (8/1379) 
Abbreviations: eGFR, estimated glomerular filtration rate; LVEF: Left ventricular ejection fraction; SD, standard 
deviation. 
Available demographic data for patients who were excluded from the study due to either clinical 
or sample criteria are presented in Appendix Table 3. 
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DISCUSSION 
We describe the design and rationale of a large prospective multicenter, international trial 
primarily focused on NT-proBNP testing in ED patients presenting with acute dyspnea.  In our 
study, performed in 19 North American institutions, we enrolled a population of patients 
representative of a contemporary cohort of patients presenting with acute dyspnea in whom 
natriuretic peptide testing would be contemplated.  The central goal of this trial is to determine 
the most useful diagnostic cut-offs for this biomarker for the diagnosis of acute HF in a 
contemporary cohort of patients presenting with acute dyspnea.  Additionally, this will be one of 
the first studies prospectively examining the role of in-hospital NT-proBNP monitoring for 
predicting prognosis after hospital-based treatment for acute HF.  
To aid in early diagnosis of patients with acute dyspnea in the ED, readily available, accurate, 
and objective tools to support clinical judgment are needed.(26, 27) Early and correct diagnosis 
is essential, as delayed treatment for acute HF is associated with increased mortality.(28) 
Improvement in patient care after HF hospitalization is a major centerpiece of current efforts to 
control cost (29); accurate and rapid diagnosis of HF after admission to the emergency 
department would be expected to have a cascade effect on both the patient and the health care 
system, translating into prompt and proper treatment with subsequent reduction of the length of 
hospital stay and improvement in patient outcomes. Prior studies from PRIDE(30, 31) and the 
Canadian based Improved Management of Patients with Congestive Heart Failure (IMPROVE-
CHF) study(6) suggest that prompt, accurate diagnosis would reduce indecision, potentially 
improve outcomes, and lead to reduction in healthcare expenditures. The validation of the ICON 
diagnostic cutoffs in a contemporary cohort may thus aid in enhancing diagnosis of acute HF in 
the emergency department. 
In addition to its value in diagnosis, NT-proBNP concentrations are associated with HF severity 
and are guideline supported for predicting short- to intermediate-term risk for adverse outcomes, 
such as death or repeat hospitalization. As shown by the first ICON investigators, NT-proBNP 
concentrations >5180 pg/mL were associated with an adjusted odds ratio of 5.20 (95% 
confidence intervals [CI] = 2.20–8.10, P<.001) for death by 76 days.(3) Longer term follow-up 
of the PRIDE study demonstrated similar prognostic value of the baseline NT-proBNP 
measurement through four years.(18) More recent data have suggested value of serial 
measurement of NT-proBNP to better assess risk. Whereas a baseline measurement of NT-
proBNP is useful for prognosis, subsequent re-measurement of the peptide after treatment for 
acute HF is of even greater predictive importance.(19-21)  Although not yet supported by large-
scale prospective data, retrospective research indicates that two factors appear to be 
independently predictive of event-free survival after hospitalization for AHF: significant 
reduction of NT-proBNP concentration (≥30%) and lower absolute NT-proBNP values at 
discharge.(20) The ICON-RELOADED study will prospectively assess the importance of in-
hospital change in NT-proBNP as a prognostic indicator of short-term hazard. 
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The ability to determine disease severity and subsequently tailor therapeutic response has the 
potential to maximize proper care, minimize resource use, and improve healthcare outcomes. For 
example, results from in-hospital NT-proBNP testing could be incorporated into each of the three 
strategies proposed by Dunbar-Yaffe et al. to reduce readmissions for HF: (1) identify patients at 
high risk of readmission prior to their index hospital discharge; (2) institute remote ambulatory 
monitoring strategies to identify early warning signs before acute decompensation takes place, 
and (3) employ strategies in the emergency department to identify low-risk patients who may not 
need hospital readmission.(32) Of particular importance in the current health care environment in 
the United States is the goal of reducing 30-day hospital readmission rates for HF(29, 33), not 
only to improve patient outcomes, but also to mitigate the financial penalties associated with 
excess readmission rates during the first 30 days after discharge.(34)   
A few limitations should be considered with the eventual interpretation of this study’s findings. 
The applicability of data generated from this North American cohort should be considered when 
applying the results in venues outside of the United States and Canada.  Additionally, a relatively 
high percentage of samples (13%) were excluded from the analysis due to various sample 
exclusion criteria, possibly omitting eligible subjects. However given the central goal of this trial 
was focused on assay validation, such exclusions are mandated. Although not tested for 
significance, in comparison with the original ICON study cohort,(26) the patients in the present 
study were numerically younger (mean 56.4 vs. 68.3 years old), less likely to have prior heart 
failure (24.9% vs. 34%), prior MI (13.2% vs. 25%), or prior coronary artery disease (21.2% vs. 
40%); and more likely to have hypertension (63.3% vs. 53%).  Females comprised about 49% of 
each of the studies’ patient populations. As well, though results of local natriuretic peptide 
testing were redacted from the CEC processes, such results could theoretically influence 
behaviors of clinicians during patient hospitalization and care. 
CONCLUSION 
The ICON-RELOADED Study will validate NT-proBNP diagnostic cutoffs in a modern 
multicenter cohort of patients, an important step to understanding the optimal diagnostic 
application of this biomarker in emergency department patients. Furthermore, the study will 
carefully examine the role of in-hospital NT-proBNP monitoring, which may provide insights to 
better manage patients following hospitalization for acute HF. More accurate and timely 
diagnosis combined with more precise management of the HF patient may improve outcomes, in 
part due to better management of higher risk patients, while simultaneously reducing the burden 
of healthcare expenditures.  
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HIGHLIGHTS 
 NT-proBNP facilitates diagnosis, prognosis, and treatment of acute heart failure 
 
 Change in patient demographics require updated diagnostic NT-proBNP cutoffs 
 
 ICON-RELOADED aims to determine diagnostic NT-proBNP cutoffs in a sample of 
1461 patients 
 
 Prognostic value of in-hospital change in NT-proBNP  will be assessed 
 
CLINICAL PERSPECTIVES: 
More accurate diagnosis of acute HF can lead to more efficient triage, more accurate therapeutic 
focus, reduced hospital length of stay, reduced medical expenditures, reduced disease 
complications, and improved clinical outcomes. In a contemporary cohort of patients presenting 
to the Emergency Department, the ICON-RELOADED Study will validate NT-proBNP 
thresholds of 450/900/1800 pg/mL for age categories of <50/50–75/≥75 years for diagnosis of 
acute HF in a modern cohort of patients who present to the ED with acute dyspnea. Additionally, 
better understanding of the use of NT-proBNP for disease prognosis in acute HF may be 
associated with similar positive clinical implications.  
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APPENDIX 
Clinical endpoint committee charter definitions for adjudication of events.  Definitions are 
based on regulatory guidance
1
or clinical practice guidelines. 
ACUTE HEART FAILURE 
 
Clinical manifestations of heart failure: 
 
a) New or worsening symptoms of heart failure (at least 1 of the following): 
 Dyspnea 
 Orthopnea 
 Paroxysmal nocturnal dyspnea 
 Increased fatigue or worsening exercise tolerance 
 Worsening swelling of the legs 
 Gastrointestinal distress related to congestion/low output  
 
AND 
 
b) New or worsening signs of heart failure (at least 2 of the following): 
 Pulmonary edema 
 Pulmonary basilar crackles 
 Jugular venous distension / elevated jugular venous pressure / positive hepato-
jugular reflux 
 Peripheral edema 
 Rapid weight gain 
 New or worsening third heart sound or gallop rhythm 
 Increased abdominal distension or ascites 
 Hepatomegaly (not related to liver disease) 
 Radiological evidence of worsening heart failure 
 Changes in biomarker (e.g., B-type natriuretic peptide or amino-terminal pro-B 
type natriuretic peptide) above local reference limits 
 Invasive or non-invasive tests showing elevated cardiac feeling pressures or low 
cardiac output 
 
AND 
 
c) Additional/increased therapy (at least 1 of the following): 
 
 Initiation of oral diuretic, intravenous diuretic, inotrope, or vasodilator therapy 
 Uptitration of oral diuretic, intravenous therapy (if already on therapy) 
 Initiation of mechanical or surgical intervention (mechanical circulatory support, 
heart transplantation or ventricular pacing to improve cardiac function), or the use 
                                                          
1
 Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular 
Endpoint Events in Clinical Trials. Circulation. 2015;132(4):302-61. 
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of ultrafiltration, hemofiltration, or dialysis that is specifically directed at 
treatment of heart failure 
 
ACUTE DYSPNEA 
 
A subjective feeling of shortness of breath, difficult or labored breathing, arising or worsening 
over the course of no longer than several days. 
 
DEATH 
 
All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. 
Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac 
disease (e.g., cancer, infection) should be classified as cardiac. 
 
 Cardiac death  
Any death due to proximate cardiac cause (e.g., MI, low-output failure, fatal arrhythmia), 
unwitnessed death and death of unknown cause, and all procedure-related deaths, including those 
related to concomitant treatment, will be classified as cardiac death. 
 
o Cardiac death due to heart failure 
 New or worsening signs and/or symptoms of heart failure include any of the 
signs and symptoms as detailed above for ADHF 
 
o Cardiac death due to myocardial infarction 
 New or worsening signs and/or symptoms of myocardial infarction leading to 
death within 30 days 
 
o Sudden cardiac death or primary arrhythmia: refers to death that occurs unexpectedly 
in a previously stable patient and includes the following deaths: 
 Witnessed and instantaneous without new or worsening symptoms 
 Witnessed within 60 minutes of the onset of new or worsening cardiac 
symptoms 
 Witnessed and attributed to an identified arrhythmia (e.g., captured on an 
electrocardiographic (ECG) recording or witnessed on a monitor by either a 
medic or paramedic) 
 Subjects unsuccessfully resuscitated from cardiac arrest or successfully 
resuscitated from cardiac arrest but who die within 24 hours without 
identification of a non-cardiac etiology 
o Other cardiac death 
 Cardiac death not meeting definitions of sudden cardiac death or death due to 
heart failure 
 Vascular death  
Death caused by non-coronary vascular causes, such as cerebrovascular disease, pulmonary 
embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular diseases. 
 
 Non-cardiovascular death 
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Any death not covered by the above definitions, such as death caused by infection, malignancy, 
sepsis, pulmonary causes, accident, suicide, or trauma. 
HEART FAILURE HOSPITALIZATION 
Unplanned presentation to an acute care facility for an exacerbation of heart failure requiring an 
overnight stay (change in calendar day), due to signs and symptoms compatible with acute HF as 
defined above. 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
24 
 
Appendix Table 1. Elecsys
®
  Description 
Topic Elecsys proBNP II Elecsys proBNP II STAT 
Test Principle The Elecsys proBNP II Assay 
components are a two-step sandwich 
immunoassay with streptavidin 
microparticles and 
electrochemiluminescent detection.  
The total duration of the test system is 
~18 minutes.  
The Elecsys proBNP II STAT Assay 
components are a two-step sandwich 
immunoassay with streptavidin 
microparticles and 
electrochemiluminescent detection. 
The total duration of the test system 
is 9 minutes.   
Incubation 1st incubation: Antigen in the sample 
(15 μL), a biotinylated monoclonal NT-
proBNP-specific antibody, and a 
monoclonal NT-proBNP-specific 
antibody labeled with a ruthenium 
complex form a sandwich complex. 
2nd incubation: After addition of 
streptavidin-coated microparticles, the 
complex becomes bound to the solid 
phase via interaction of biotin and 
streptavidin. 
During a nine (9) minute incubation, 
antigen in the sample (15 μL), a 
biotinylated monoclonal NT-
proBNP-specific antibody, a 
monoclonal NT-proBNP-specific 
antibody labeled with a ruthenium 
complex and streptavidin-coated 
microparticles react to form a 
sandwich complex, which is bound to 
the solid phase. 
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Appendix Table 2. Site and Investigator List 
Site Name Investigator Location 
Baylor College of Medicine Peacock, Frank Houston, TX, USA 
Beth Israel Deaconess Medical Center Shapiro, Nathan Boston, MA, USA 
Henry Ford Hospital Nowak, Richard Detroit, MI, USA 
Jewish General Hospital Chen-Tournoux, Annabel Montreal, QC, Canada 
Loma Linda University Health Walters , Elizabeth Loma Linda, CA, USA 
Massachusetts General Hospital Nagurney, John Boston, MA, USA 
Methodist Hospital Pang, Peter Indianapolis, IN, USA 
Stony Brook University Medical Center Singer, Adam Stony Brook, NY, USA 
Thomas Jefferson University Hollander, Judd 
Chang, Anna Marie 
Philadelphia, PA, USA 
Toronto General Hospital Ross, Heather Toronto, ON, Canada 
Torrance Memorial Medical Center Lurie, Mark Torrance, CA, USA 
University of Kansas Hospital Cannon, Chad Kansas City, KS, USA 
University of Maryland Medical Center Christenson, Robert Baltimore, MD, USA 
University of Southern California Arora, Sanjay Los Angeles, CA, USA 
University of Texas Health Science Center at San 
Antonio 
DeLorenzo, Robert 
San Antonio, TX, USA 
University of Texas Southwestern Medical Center Blomkalns, Andra Dallas, TX, USA 
University of Washington Cheng, Richard Seattle, WA, USA 
Wake Forest Health Sciences Hiestand, Brian Winston-Salem, NC, 
USA 
Wayne State University Levy, Phillip Detroit, MI, USA 
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Appendix Table 3. Characteristics of patients whose samples were excluded from analyses 
due to clinical or sample exclusion criteria. 
Characteristic 
 
N=297 Subjects 
Demographics  
Age (years) (Mean ± SD (N)) 55.1±15.5 (297) 
Female Sex 52.2% (155/297) 
Hispanic or Latino 17.2% (50/290) 
Nonwhite Race 48.6% (140/288) 
Abbreviations: eGFR, estimated glomerular filtration rate; LVEF: Left ventricular ejection fraction; SD, standard 
deviation 
